Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
Open Access
- 12 February 2018
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 7 (6) , e1428158
Abstract
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 antibody rituximab. In recent years, new antibodies against CD20 have been developed including ofatumumab and obinutuzumab. An important mechanism of action of therapeutic monoclonal antibodies is activation of immune cells via Fc receptors (FcγRs). However, surprisingly, little is known about triggering of FcγRs by different therapeutic antibodies in general and anti-CD20 antibodies in particular. Here we establish a reporter assay to assess whether a particular antibody activates a certain Fc receptor. Using this assay we corroborated previous reports demonstrating obinutuzumab's ability to highly activate FcγRIIIa (CD16a). Importantly, we discovered that obinutuzumab also activates FcγRI (CD64) significantly more than rituximab and ofatumumab in response to chronic lymphocytic leukemia (CLL) cells obtained from patients. Mechanistically we show that this is due to the lack of FcγRIIb-mediated internalization of obinutuzumab following binding to CD20. Moreover, we show that obinutuzumab induces increased phagocytosis by primary macrophages in an FcγRI-dependent manner. Beyond the discovery of a new mechanism of obinutuzumab activity, the reporter assay can be applied to other therapeutic antibodies and may assist in developing antibodies with improved immunological properties.Keywords
Funding Information
- Israel Science Foundation
- German Israel Foundation
- EC | European Research Council
This publication has 30 references indexed in Scilit:
- Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodiesBlood, 2015
- The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering TechnologyJournal of Pharmaceutical Sciences, 2015
- Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosisJournal of Clinical Investigation, 2014
- Immune evasion by oncogenic proteins of acute myeloid leukemiaBlood, 2014
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft ModelsMolecular Cancer Therapeutics, 2013
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)Blood, 2013
- A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptorsJournal of Immunological Methods, 2013
- Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.2010
- Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsBlood, 2004
- Ligand Binding and Phagocytosis by CD16 (Fc γ Receptor III) IsoformsJournal of Biological Chemistry, 1995